186 related articles for article (PubMed ID: 8905027)
1. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy.
Pelosio P; Barbareschi M; Bonoldi E; Marchetti A; Verderio P; Caffo O; Bevilacqua P; Boracchi P; Buttitta F; Barbazza R; Dalla Palma P; Gasparini G
Ann Oncol; 1996 Sep; 7(7):695-703. PubMed ID: 8905027
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients.
Gasparini G; Toi M; Verderio P; Ranieri G; Dante S; Bonoldi E; Boracchi P; Fanelli M; Tominaga T
Int J Oncol; 1998 May; 12(5):1117-25. PubMed ID: 9538138
[TBL] [Abstract][Full Text] [Related]
3. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.
Michalides R; Hageman P; van Tinteren H; Houben L; Wientjens E; Klompmaker R; Peterse J
Br J Cancer; 1996 Mar; 73(6):728-34. PubMed ID: 8611372
[TBL] [Abstract][Full Text] [Related]
4. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.
Wani G; Noyes I; Milo GE; D'Ambrosio SM
Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 and prognosis in human breast cancer.
Gillett C; Smith P; Gregory W; Richards M; Millis R; Peters G; Barnes D
Int J Cancer; 1996 Apr; 69(2):92-9. PubMed ID: 8608989
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value.
van Diest PJ; Michalides RJ; Jannink L; van der Valk P; Peterse HL; de Jong JS; Meijer CJ; Baak JP
Am J Pathol; 1997 Feb; 150(2):705-11. PubMed ID: 9033283
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.
Gasparini G; Toi M; Biganzoli E; Dittadi R; Fanelli M; Morabito A; Boracchi P; Gion M
Oncology; 2001; 60(1):72-80. PubMed ID: 11150912
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.
Zukerberg LR; Yang WI; Gadd M; Thor AD; Koerner FC; Schmidt EV; Arnold A
Mod Pathol; 1995 Jun; 8(5):560-7. PubMed ID: 7675778
[TBL] [Abstract][Full Text] [Related]
11. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients.
Gasparini G; Fox SB; Verderio P; Bonoldi E; Bevilacqua P; Boracchi P; Dante S; Marubini E; Harris AL
Clin Cancer Res; 1996 Jul; 2(7):1191-8. PubMed ID: 9816287
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma.
Kallakury BV; Sheehan CE; Ambros RA; Fisher HA; Kaufman RP; Ross JS
Cancer; 1997 Aug; 80(4):753-63. PubMed ID: 9264360
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients.
Reed W; Flørems VA; Holm R; Hannisdal E; Nesland JM
Virchows Arch; 1999 Aug; 435(2):116-24. PubMed ID: 10599310
[TBL] [Abstract][Full Text] [Related]
14. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors.
Courjal F; Louason G; Speiser P; Katsaros D; Zeillinger R; Theillet C
Int J Cancer; 1996 Aug; 69(4):247-53. PubMed ID: 8797862
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
16. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
Hwang TS; Han HS; Hong YC; Lee HJ; Paik NS
Pathol Int; 2003 Feb; 53(2):74-80. PubMed ID: 12588434
[TBL] [Abstract][Full Text] [Related]
18. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma--results of a multiparametric study.
Bevilacqua P; Barbareschi M; Verderio P; Boracchi P; Caffo O; Dalla Palma P; Meli S; Weidner N; Gasparini G
Breast Cancer Res Treat; 1995; 36(2):205-17. PubMed ID: 8534868
[TBL] [Abstract][Full Text] [Related]
20. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
